Re: Robert J. van Soest, Ellen S. de Morrée, Charlotte F. Kweldam, et al. Targeting the Androgen Receptor Confers in Vivo Cross-resistance between Enzalutamide and Docetaxel, but Not Cabazitaxel, in Castration-resistant Prostate Cancer. Eur Urol 2015;67:981-5

Masaki Shiota; Akira Yokomizo

doi:10.1016/j.eururo.2015.07.025

Re: Robert J. van Soest, Ellen S. de Morrée, Charlotte F. Kweldam, et al. Targeting the Androgen Receptor Confers in Vivo Cross-resistance between Enzalutamide and Docetaxel, but Not Cabazitaxel, in Castration-resistant Prostate Cancer. Eur Urol 2015;67:981-5

Research output: Contribution to journal › Letter › peer-review

Original language	English
Pages (from-to)	e41-e42
Journal	European Urology
Volume	69
Issue number	3
DOIs	https://doi.org/10.1016/j.eururo.2015.07.025
Publication status	Published - Mar 1 2016

All Science Journal Classification (ASJC) codes

Urology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.eururo.2015.07.025

Cite this

Shiota, M., & Yokomizo, A. (2016). Re: Robert J. van Soest, Ellen S. de Morrée, Charlotte F. Kweldam, et al. Targeting the Androgen Receptor Confers in Vivo Cross-resistance between Enzalutamide and Docetaxel, but Not Cabazitaxel, in Castration-resistant Prostate Cancer. Eur Urol 2015;67:981-5. European Urology, 69(3), e41-e42. https://doi.org/10.1016/j.eururo.2015.07.025

Re : Robert J. van Soest, Ellen S. de Morrée, Charlotte F. Kweldam, et al. Targeting the Androgen Receptor Confers in Vivo Cross-resistance between Enzalutamide and Docetaxel, but Not Cabazitaxel, in Castration-resistant Prostate Cancer. Eur Urol 2015;67:981-5. / Shiota, Masaki; Yokomizo, Akira.

In: European Urology, Vol. 69, No. 3, 01.03.2016, p. e41-e42.

Research output: Contribution to journal › Letter › peer-review

Shiota, M & Yokomizo, A 2016, 'Re: Robert J. van Soest, Ellen S. de Morrée, Charlotte F. Kweldam, et al. Targeting the Androgen Receptor Confers in Vivo Cross-resistance between Enzalutamide and Docetaxel, but Not Cabazitaxel, in Castration-resistant Prostate Cancer. Eur Urol 2015;67:981-5', European Urology, vol. 69, no. 3, pp. e41-e42. https://doi.org/10.1016/j.eururo.2015.07.025

@article{a2a93335ce744e6399114a19b3f7ebbe,

title = "Re: Robert J. van Soest, Ellen S. de Morr{\'e}e, Charlotte F. Kweldam, et al. Targeting the Androgen Receptor Confers in Vivo Cross-resistance between Enzalutamide and Docetaxel, but Not Cabazitaxel, in Castration-resistant Prostate Cancer. Eur Urol 2015;67:981-5",

author = "Masaki Shiota and Akira Yokomizo",

year = "2016",

month = mar,

day = "1",

doi = "10.1016/j.eururo.2015.07.025",

language = "English",

volume = "69",

pages = "e41--e42",

journal = "European Urology",

issn = "0302-2838",

publisher = "Elsevier",

number = "3",

}

TY - JOUR

T1 - Re

T2 - Robert J. van Soest, Ellen S. de Morrée, Charlotte F. Kweldam, et al. Targeting the Androgen Receptor Confers in Vivo Cross-resistance between Enzalutamide and Docetaxel, but Not Cabazitaxel, in Castration-resistant Prostate Cancer. Eur Urol 2015;67:981-5

AU - Shiota, Masaki

AU - Yokomizo, Akira

PY - 2016/3/1

Y1 - 2016/3/1

UR - http://www.scopus.com/inward/record.url?scp=84937510911&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84937510911&partnerID=8YFLogxK

U2 - 10.1016/j.eururo.2015.07.025

DO - 10.1016/j.eururo.2015.07.025

M3 - Letter

C2 - 26215602

AN - SCOPUS:84937510911

SN - 0302-2838

VL - 69

SP - e41-e42

JO - European Urology

JF - European Urology

IS - 3

ER -

Re: Robert J. van Soest, Ellen S. de Morrée, Charlotte F. Kweldam, et al. Targeting the Androgen Receptor Confers in Vivo Cross-resistance between Enzalutamide and Docetaxel, but Not Cabazitaxel, in Castration-resistant Prostate Cancer. Eur Urol 2015;67:981-5

All Science Journal Classification (ASJC) codes

UN SDGs

Access to Document

Other files and links

Cite this